While the direct influence of IL-2 on platelets remains elusive, preliminary investigations have reported adverse outcomes such as thrombocytopenia with increased viability of residual platelets with moderate and high-dose IL-2 treatment in cancer patients [57]. The gene discussed is IL2; the disease is Thrombocytopenia.